Antiobesity effects of chronic cannabinoid CB 1 receptor antagonist treatment in diet-induced obese mice

By Hildebrandt A.L.   Kelly-Sullivan D.M.   Black S.C.  

European Journal of Pharmacology, Vol. 462, Iss. 1, 2003-02 ,pp. : 125-132

Elsevier

Access to resources Recommend Favorite

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice

By Joharapurkar Amit   Dhanesha Nirav   Kshirsagar Samadhan   Patel Kartik   Bahekar Rajesh   Shah Gaurang   Jain Mukul  

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 12, 2013-01 ,pp. : 1009-1015

NRC Research Press

Access to resources Recommend Favorite

Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB 1 receptor knockout mice

By Mascia M.S.   Obinu M.C.   Ledent C.   Parmentier M.   Bohme G.A.   Imperato A.   Fratta W.  

European Journal of Pharmacology, Vol. 383, Iss. 3, 1999-11 ,pp. : 1-2

Elsevier

Access to resources Recommend Favorite

Influence of arachidonyl‐2′‐chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute side‐effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock‐induced seizure model and chimney test in mice

By  

Fundamental & Clinical Pharmacology, Vol. 29, Iss. 4, 2015-08 ,pp. : 382-393

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2141-2144

Informa Healthcare

Access to resources Recommend Favorite